Amgen /
ChemoCentryx, Inc.
Amgen Completes Acquisition of ChemoCentryx, Inc.
- Price
- $3.7bn
- Stage
- Closed
What happened
Amgen Inc. completed its acquisition of ChemoCentryx, Inc. on Oct. 20, 2022. The transaction represented aggregate merger consideration of approximately $3.7 billion.
ChemoCentryx focuses on orally administered therapeutics for autoimmune diseases, inflammatory disorders and cancer.
Who is involved, and the source
Everything on this page comes from the source below.
Advisers
Target
- Fairness opinion to the targetGoldman SachsAdviser profile
- Financial adviser to the targetGoldman SachsAdviser profile
Advisers are not parties to the deal.
Amgen Completes Acquisition of ChemoCentryx, Inc.
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly